2021-03-01: Introducing SARS-CoV-2 UTAB FS
DiaSys is particularly pleased to announce the launch of SARS-CoV-2 UTAB FS assay. The test for quantitative determination of total antibodies against the severe acute respiratory syndrome associated coronavirus 2 (SARS-CoV-2) allows to detect an already passed infection and serves to verify the efficacy of new vaccines.
The assay specifically detects antibodies directed against the receptor-binding domain (RBD) of the viral spike protein; a region that allows viral entry via binding to the host cell angiotensin-converting enzyme 2 (ACE2) receptor. Studies have shown that antibodies against the RBD in the spike protein exhibit a neutralizing effect and may block viral entry into cells. Due to the importance of neutralizing antibodies, DiaSys selected the RBD as the target antigen for the assay to determine total antibodies in COVID-19.
Quantitative determination of antibodies to SARS-CoV-2 is becoming increasingly important as it provides a good assessment of the actual spread of COVID-19 infections. It plays an important role in characterizing a vaccine-induced immune response and allows quantification of antibody levels in plasmapheresis donations used to treat COVID-19 patients with a severe course.
SARS-CoV-2 UTAB FS is an immunoturbidimetric test to determine total antibodies in human serum. The test is characterized by high specificity and sensitivity and shows no cross-reactivity with antibodies present to other seasonal cold pathogens from the corona virus group (OC43, 229E, NL63, HKU1).
The test provides comparable results on almost all clinical chemistry analyzers. It enables reliable monitoring of patients, which is currently a major challenge, especially in the context of testing the efficacy of new vaccines, as available antibody tests have different reaction principles and can usually only be used on the manufacturers' platforms.
The liquid stable, ready-to-use reagent with matched calibrators, controls and sample dilution matrix is available now.